Rosuvastatin Calcium Clopidogrel Capsule
Description
ROSUROOT-CP
Rosuvastatin Calcium and Clopidogrel Capsules
Division: DIABGLYM
Composition
Each hard gelatin capsule contains:
Rosuvastatin Calcium IP equivalent to Rosuvastatin — 10 mg / 20 mg
Clopidogrel Bisulphate IP equivalent to Clopidogrel — 75 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Hard gelatin oral capsule
Product Description
ROSUROOT-CP is a cardio-protective combination of Rosuvastatin and Clopidogrel, formulated for the prevention and management of atherosclerotic cardiovascular disease, acute coronary syndrome, post-myocardial infarction care, ischemic stroke prevention, and peripheral arterial disease. This combination provides dual cardiovascular protection by controlling dyslipidemia and preventing platelet aggregation, thereby reducing the risk of recurrent cardiovascular events.
Rosuvastatin is a potent HMG-CoA reductase inhibitor that effectively lowers LDL cholesterol, stabilizes atherosclerotic plaques, reduces vascular inflammation, and decreases cardiovascular morbidity and mortality. Clopidogrel is an antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation, helping prevent thrombus formation in patients with coronary artery disease and cerebrovascular disease.
ROSUROOT-CP is particularly beneficial in patients with established cardiovascular disease, diabetes, hypertension, dyslipidemia, previous myocardial infarction, previous stroke, or those requiring long-term secondary prevention of cardiovascular events.
Technical Knowledge of Rosuvastatin and Clopidogrel
Rosuvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing LDL receptor activity, resulting in significant reduction of LDL cholesterol, total cholesterol, and non-HDL cholesterol. It also provides plaque stabilization and anti-inflammatory vascular benefits.
Clopidogrel is a prodrug that undergoes hepatic activation and selectively inhibits the platelet P2Y12 ADP receptor. This inhibition prevents ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation and thrombus formation.
The combination of Rosuvastatin and Clopidogrel addresses both lipid-related atherosclerosis and platelet-mediated thrombosis, providing comprehensive cardiovascular risk reduction.
Mechanism of Action
Rosuvastatin reduces hepatic cholesterol synthesis, increases LDL receptor expression, lowers LDL cholesterol and total cholesterol, reduces vascular inflammation, and stabilizes atherosclerotic plaques.
Clopidogrel inhibits the platelet P2Y12 receptor, prevents ADP-induced platelet aggregation, reduces thrombus formation, and provides long-term antiplatelet protection.
Key Benefits
Effective LDL cholesterol reduction
Prevents platelet aggregation and thrombosis
Reduces the risk of recurrent myocardial infarction
Supports secondary prevention of ischemic stroke
Stabilizes atherosclerotic plaques
Provides comprehensive cardiovascular protection
Beneficial in diabetic cardiovascular patients
Suitable for long-term cardiovascular management under medical supervision
Clinical Applications
ROSUROOT-CP is commonly prescribed for coronary artery disease, acute coronary syndrome, post-myocardial infarction therapy, ischemic stroke prevention, transient ischemic attack prevention, peripheral arterial disease, diabetic cardiovascular disease, dyslipidemia with cardiovascular risk, and secondary prevention of atherosclerotic cardiovascular events.
Facts About Rosuvastatin and Clopidogrel
Rosuvastatin is among the most effective statins for intensive LDL cholesterol reduction and cardiovascular risk reduction. Clopidogrel is one of the most widely used antiplatelet agents for preventing arterial thrombosis and recurrent cardiovascular events. The combination is extensively used in high-risk cardiovascular patients requiring both lipid-lowering and antiplatelet therapy.
Key Facts
Dual cardiovascular protection therapy
Rosuvastatin for intensive lipid lowering
Clopidogrel for effective antiplatelet protection
Reduces atherosclerotic and thrombotic cardiovascular risk
Supports long-term secondary prevention strategies
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROSUROOT-CP is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, diabetes, hypertension, stroke, and dyslipidemia creates strong prescription demand and long-term market potential for this combination.
Why Choose ROSUROOT-CP for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin and Clopidogrel Capsules with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled capsule manufacturing
Blister and Alu-Alu packaging options
ROSUROOT-CP from DIABGLYM combines intensive lipid lowering, effective antiplatelet therapy, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based cardiovascular combination.
